{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T06:28:35Z","timestamp":1790317715639,"version":"4.1.0"},"reference-count":40,"publisher":"American Medical Association (AMA)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"DOI":"10.1001\/jamanetworkopen.2019.19284","type":"journal-article","created":{"date-parts":[[2020,1,15]],"date-time":"2020-01-15T11:50:23Z","timestamp":1579089023000},"page":"e1919284","source":"Crossref","is-referenced-by-count":53,"title":["Association of Baseline Prostate-Specific Antigen Level With Long-term Diagnosis of Clinically Significant Prostate Cancer Among Patients Aged 55 to 60 Years"],"prefix":"10.1001","volume":"3","author":[{"given":"Evan","family":"Kovac","sequence":"first","affiliation":[{"name":"Glickman Urological and Kidney Institute, Cleveland Clinic Foundation, Cleveland, Ohio"},{"name":"Department of Urology, Montefiore Medical Center, Bronx, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sigrid V.","family":"Carlsson","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York"},{"name":"Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York"},{"name":"Department of Urology, Institute of Clinical Sciences, Sahlgrenska Academy at University of Gothenburg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Lilja","sequence":"additional","affiliation":[{"name":"Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York"},{"name":"Department of Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York"},{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York"},{"name":"Nuffield Department of Surgical Sciences, University of Oxford, Oxford, United Kingdom"},{"name":"Department of Translational Medicine, Lund University, Malm\u00f6, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas","family":"Hugosson","sequence":"additional","affiliation":[{"name":"Department of Urology, Institute of Clinical Sciences, Sahlgrenska Academy at University of Gothenburg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael W.","family":"Kattan","sequence":"additional","affiliation":[{"name":"Department of Quantitative Health Sciences, Cleveland Clinic Foundation, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Holmberg","sequence":"additional","affiliation":[{"name":"Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy at University of Gothenburg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Stephenson","sequence":"additional","affiliation":[{"name":"Department of Surgery, Division of Urology, Rush Medical College, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2020,1,15]]},"reference":[{"issue":"1","key":"zoi190720r1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.v69.1","article-title":"Cancer statistics, 2019.","volume":"69","author":"Siegel","year":"2019","journal-title":"CA Cancer J Clin"},{"issue":"6","key":"zoi190720r2","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1016\/j.eururo.2013.12.062","article-title":"Overdiagnosis and overtreatment of prostate cancer.","volume":"65","author":"Loeb","year":"2014","journal-title":"Eur Urol"},{"issue":"2","key":"zoi190720r3","doi-asserted-by":"publisher","first-page":"120","DOI":"10.7326\/0003-4819-157-2-201207170-00459","article-title":"Screening for prostate cancer: US Preventive Services Task Force recommendation statement.","volume":"157","author":"Moyer","year":"2012","journal-title":"Ann Intern Med"},{"issue":"18","key":"zoi190720r4","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1001\/jama.2018.3710","article-title":"Screening for prostate cancer: US Preventive Services Task Force recommendation statement.","volume":"319","author":"Grossman","year":"2018","journal-title":"JAMA"},{"issue":"7","key":"zoi190720r5","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1001\/jama.2018.19941","article-title":"Use of active surveillance or watchful waiting for low-risk prostate cancer and management trends across risk groups in the United States, 2010-2015.","volume":"321","author":"Mahal","year":"2019","journal-title":"JAMA"},{"issue":"1","key":"zoi190720r6","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1001\/jama.2015.6036","article-title":"Trends in management for patients with localized prostate cancer, 1990-2013.","volume":"314","author":"Cooperberg","year":"2015","journal-title":"JAMA"},{"issue":"10","key":"zoi190720r7","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.acuro.2015.05.003","article-title":"Baseline PSA in a Spanish male population aged 40-49 years anticipates detection of prostate cancer.","volume":"39","author":"Angulo","year":"2015","journal-title":"Actas Urol Esp"},{"issue":"3","key":"zoi190720r8","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/S0090-4295(01)01304-8","article-title":"Low levels of prostate-specific antigen predict long-term risk of prostate cancer: results from the Baltimore Longitudinal Study of Aging.","volume":"58","author":"Fang","year":"2001","journal-title":"Urology"},{"issue":"4","key":"zoi190720r9","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1200\/JCO.2006.06.9351","article-title":"Long-term prediction of prostate cancer up to 25 years before diagnosis of prostate cancer using prostate kallikreins measured at age 44 to 50 years.","volume":"25","author":"Lilja","year":"2007","journal-title":"J Clin Oncol"},{"issue":"5","key":"zoi190720r10","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1016\/j.eururo.2011.11.007","article-title":"Prostate-specific antigen and long-term prediction of prostate cancer incidence and mortality in the general population.","volume":"61","author":"Orsted","year":"2012","journal-title":"Eur Urol"},{"issue":"23","key":"zoi190720r11","doi-asserted-by":"publisher","first-page":"2705","DOI":"10.1200\/JCO.2016.66.7527","article-title":"Baseline prostate-specific antigen levels in midlife predict lethal prostate cancer.","volume":"34","author":"Preston","year":"2016","journal-title":"J Clin Oncol"},{"key":"zoi190720r12","doi-asserted-by":"publisher","first-page":"c4521","DOI":"10.1136\/bmj.c4521","article-title":"Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study.","volume":"341","author":"Vickers","year":"2010","journal-title":"BMJ"},{"issue":"13","key":"zoi190720r13","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1056\/NEJMoa0810696","article-title":"Mortality results from a randomized prostate-cancer screening trial.","volume":"360","author":"Andriole","year":"2009","journal-title":"N Engl J Med"},{"issue":"6","key":"zoi190720r14","doi-asserted-by":"publisher","first-page":"273S","DOI":"10.1016\/S0197-2456(00)00098-2","article-title":"Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial.","volume":"21","author":"Prorok","year":"2000","journal-title":"Control Clin Trials"},{"issue":"5","key":"zoi190720r15","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1111\/bju.2019.123.issue-5","article-title":"Extended follow-up for prostate cancer incidence and mortality among participants in the Prostate, Lung, Colorectal and Ovarian randomized cancer screening trial.","volume":"123","author":"Pinsky","year":"2018","journal-title":"BJU Int"},{"issue":"4","key":"zoi190720r16","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1177\/1740774510374091","article-title":"Assessing contamination and compliance in the prostate component of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial.","volume":"7","author":"Pinsky","year":"2010","journal-title":"Clin Trials"},{"issue":"18","key":"zoi190720r17","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1056\/NEJMc1515131","article-title":"Reevaluating PSA testing rates in the PLCO Trial.","volume":"374","author":"Shoag","year":"2016","journal-title":"N Engl J Med"},{"issue":"2","key":"zoi190720r18","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.juro.2016.01.120","article-title":"Prognostic value of percent Gleason grade 4 at prostate biopsy in predicting prostatectomy pathology and recurrence.","volume":"196","author":"Cole","year":"2016","journal-title":"J Urol"},{"issue":"5","key":"zoi190720r19","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1111\/bju.2013.111.issue-5","article-title":"Prognostic Gleason grade grouping: data based on the modified Gleason scoring system.","volume":"111","author":"Pierorazio","year":"2013","journal-title":"BJU Int"},{"issue":"5","key":"zoi190720r20","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1001\/jama.1994.03510290050036","article-title":"Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer.","volume":"271","author":"Epstein","year":"1994","journal-title":"JAMA"},{"issue":"6","key":"zoi190720r21","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1002\/(ISSN)1097-0142","article-title":"Histologic differentiation, cancer volume, and pelvic lymph node metastasis in adenocarcinoma of the prostate.","volume":"66","author":"McNeal","year":"1990","journal-title":"Cancer"},{"issue":"3","key":"zoi190720r22","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/modpathol.2014.116","article-title":"Cribriform growth is highly predictive for postoperative metastasis and disease-specific death in Gleason score 7 prostate cancer.","volume":"28","author":"Kweldam","year":"2015","journal-title":"Mod Pathol"},{"issue":"9","key":"zoi190720r23","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1097\/PAS.0b013e3182556dcd","article-title":"Do adenocarcinomas of the prostate with Gleason score (GS) =6 have the potential to metastasize to lymph nodes?","volume":"36","author":"Ross","year":"2012","journal-title":"Am J Surg Pathol"},{"issue":"5.5","key":"zoi190720r24","first-page":"583","article-title":"NCCN guidelines updates: management of prostate cancer.","volume":"17","author":"Mohler","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"issue":"1","key":"zoi190720r25","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.eururo.2019.02.009","article-title":"A 16-yr follow-up of the European Randomized Study of Screening for Prostate Cancer.","volume":"76","author":"Hugosson","year":"2019","journal-title":"Eur Urol"},{"issue":"1","key":"zoi190720r26","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1080\/21681805.2017.1411392","article-title":"Eighteen-year follow-up of the G\u00f6teborg Randomized Population-based Prostate Cancer Screening Trial: effect of sociodemographic variables on participation, prostate cancer incidence and mortality.","volume":"52","author":"Hugosson","year":"2018","journal-title":"Scand J Urol"},{"issue":"3","key":"zoi190720r27","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.eururo.2018.08.032","article-title":"Baseline prostate-specific antigen level in midlife and aggressive prostate cancer in black men.","volume":"75","author":"Preston","year":"2019","journal-title":"Eur Urol"},{"issue":"6","key":"zoi190720r28","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1016\/j.eururo.2018.02.016","article-title":"Twenty-year risk of prostate cancer death by midlife prostate-specific antigen and a panel of four kallikrein markers in a large population-based cohort of healthy men.","volume":"73","author":"Sjoberg","year":"2018","journal-title":"Eur Urol"},{"issue":"1","key":"zoi190720r29","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.eururo.2016.03.026","article-title":"Screening for prostate cancer starting at age 50-54 years: a population-based cohort study.","volume":"71","author":"Carlsson","year":"2017","journal-title":"Eur Urol"},{"key":"zoi190720r30","doi-asserted-by":"publisher","first-page":"f2023","DOI":"10.1136\/bmj.f2023","article-title":"Strategy for detection of prostate cancer based on relation between prostate specific antigen at age 40-55 and long term risk of metastasis: case-control study.","volume":"346","author":"Vickers","year":"2013","journal-title":"BMJ"},{"issue":"3","key":"zoi190720r31","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.eururo.2014.10.021","article-title":"A multi-institutional prospective trial in the USA confirms that the 4Kscore accurately identifies men with high-grade prostate cancer.","volume":"68","author":"Parekh","year":"2015","journal-title":"Eur Urol"},{"issue":"1","key":"zoi190720r32","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.eururo.2014.07.034","article-title":"Preoperative prostate-specific antigen isoform p2PSA and its derivatives, %p2PSA and Prostate Health Index, predict pathologic outcomes in patients undergoing radical prostatectomy for prostate cancer: results from a multicentric European prospective study.","volume":"68","author":"Fossati","year":"2015","journal-title":"Eur Urol"},{"issue":"6","key":"zoi190720r33","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1016\/j.eururo.2017.03.025","article-title":"The single-parameter, structure-based IsoPSA assay demonstrates improved diagnostic accuracy for detection of any prostate cancer and high-grade prostate cancer compared to a concentration-based assay of total prostate-specific antigen: a preliminary report.","volume":"72","author":"Klein","year":"2017","journal-title":"Eur Urol"},{"issue":"11","key":"zoi190720r34","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1001\/jama.2009.1348","article-title":"Outcomes of localized prostate cancer following conservative management.","volume":"302","author":"Lu-Yao","year":"2009","journal-title":"JAMA"},{"issue":"3","key":"zoi190720r35","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1056\/NEJMoa1113162","article-title":"Radical prostatectomy versus observation for localized prostate cancer.","volume":"367","author":"Wilt","year":"2012","journal-title":"N Engl J Med"},{"issue":"6","key":"zoi190720r36","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1200\/JCO.2007.13.1490","article-title":"Long-term prediction of prostate cancer: prostate-specific antigen (PSA) velocity is predictive but does not improve the predictive accuracy of a single PSA measurement 15 years or more before cancer diagnosis in a large, representative, unscreened population.","volume":"26","author":"Ulmert","year":"2008","journal-title":"J Clin Oncol"},{"issue":"3","key":"zoi190720r37","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/j.urology.2013.09.075","article-title":"A commentary on PSA velocity and doubling time for clinical decisions in prostate cancer.","volume":"83","author":"Vickers","year":"2014","journal-title":"Urology"},{"issue":"11","key":"zoi190720r38","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1111\/bju.2008.102.issue-11","article-title":"Prostate cancer screening in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial: update on findings from the initial four rounds of screening in a randomized trial.","volume":"102","author":"Grubb","year":"2008","journal-title":"BJU Int"},{"issue":"1","key":"zoi190720r39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.eururo.2011.07.067","article-title":"Baseline prostate-specific antigen testing at a young age.","volume":"61","author":"Loeb","year":"2012","journal-title":"Eur Urol"},{"issue":"6","key":"zoi190720r40","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1016\/j.eururo.2013.05.022","article-title":"Prospective randomized evaluation of risk-adapted prostate-specific antigen screening in young men: the PROBASE Trial.","volume":"64","author":"Arsov","year":"2013","journal-title":"Eur Urol"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2758743\/kovac_2020_oi_190720.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,1,15]],"date-time":"2020-01-15T11:50:25Z","timestamp":1579089025000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2758743"}},"subtitle":["A Secondary Analysis of a Cohort in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial"],"short-title":[],"issued":{"date-parts":[[2020,1,15]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1,3]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2019.19284","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,15]]}}}